Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imatinib mesylate
Drug ID BADD_D01137
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status Prescription; Discontinued
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D01441
MeSH ID D000068877
PubChem ID 123596
TTD Drug ID D0AZ3C
NDC Product Code 55111-939; 64679-793; 72606-557; 63629-2067; 11722-052; 0904-6621; 60505-2901; 68382-244; 68382-245; 68001-490; 16714-705; 72485-203; 51991-376; 64679-794; 72485-202; 62068-309; 67877-634; 54893-0066; 63629-2068; 81955-0002; 72606-556; 62756-875; 68001-491; 47335-475; 70771-1394; 60505-2900; 0078-0401; 0904-6901; 60687-192; 42385-720; 0054-0249; 51991-377; 47335-472; 65344-0020; 0054-0248; 16714-704; 50268-426; 59651-240; 59651-241; 73309-059; 67877-633; 0093-7629; 42385-316; 0078-0649; 71052-670; 60687-203; 59923-723; 54893-0005; 59651-610; 0093-7630; 66499-0073; 70771-1395; 50268-427; 72969-033; 59923-724
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C30H35N7O4S
CAS Registry Number 220127-57-1
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)( =O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaLeptinP41159T79485Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myopathy15.05.05.001--Not Available
Nail discolouration23.02.05.001--
Nail disorder23.02.05.002--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity12.03.01.011; 17.02.10.002--Not Available
Neutropenia01.02.03.004--Not Available
Neutrophil count decreased13.01.06.010--
Night sweats23.02.03.006; 08.01.03.031--Not Available
Nipple pain21.05.05.009--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
Oesophagitis07.08.05.001--
Optic neuritis17.04.05.001; 10.04.10.002; 06.04.08.002--Not Available
Orbital oedema06.09.05.001--Not Available
Osteonecrosis24.04.05.004; 15.02.04.007--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palmar-plantar erythrodysaesthesia syndrome23.07.04.001; 17.02.07.009--
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Papilloedema06.09.02.002; 24.03.07.001; 17.07.02.004--
Paraesthesia17.02.06.005--
The 6th Page    First    Pre   6 7 8 9    Next   Last    Total 9 Pages